Antiangiogenic cancer therapy: Monitoring with molecular US and a clinically translatable contrast agent (BR55)

Radiology

Volumn 256, Issue 2, 2010, Pages 519-527

  Pysz, Marybeth A ^a   Foygel, Kira ^a   Rosenberg, Jarrett ^a   Gambhir, Sanjiv S ^a,b   Schneider, Michel ^c   Willmann, Jürgen K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Bracco Suisse SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BR 55; CONTRAST MEDIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B20; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; BINDING AFFINITY; CANCER MODEL; COLON CANCER; CONTROLLED STUDY; CROSS REACTION; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LONGITUDINAL STUDY; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEAR STRESS; TRANSDUCER; TUMOR XENOGRAFT; ULTRASOUND; ANIMAL; COLONIC NEOPLASMS; DIAGNOSTIC USE; DRUG DELIVERY SYSTEM; ECHOGRAPHY; GENETIC PROCEDURES; MICROBUBBLE; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MICROBUBBLES; MOLECULAR PROBE TECHNIQUES; PEPTIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY;

EID: 77955133884     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091858     Document Type: Article

References (42)

1. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
2. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer [abstr]. Cochrane Database Syst Rev 2009 July 8 (3): CD005392.
3. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92 (9): 1599-1610.
4. Mabille M, Vanel D, Albiter M, et al. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). Eur J Radiol 2009; 69 (2): 204-208.
5. Lindner JR. Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov 2004; 3 (6): 527-532. (Pubitemid 38807535)
6. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7 (7): 591-607.
7. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108 (3): 336-341.
8. Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginineleucine. Cancer Res 2005; 65 (2): 533-539.
9. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010; 51: 433-440.
10. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23 (5): 1011-1027. (Pubitemid 46202320)
11. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3 (6): 401-410.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1): 57-70.
13. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65 (10): 3967-3979.
14. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007; 37 (11): 878-886. (Pubitemid 350029203)
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3 (5): 391-400. (Pubitemid 38618122)
16. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89 (3): 488-499. (Pubitemid 30640095)
17. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000; 5 (suppl 1): 11-15.
18. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007; 13 (1): 323-330. (Pubitemid 46121886)
19. Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, Gore JC. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 2007; 26 (11): 1575-1586. (Pubitemid 351519803)
20. Palmowski M, Huppert J, Ladewig G, et al. Molecular profi ling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther 2008; 7 (1): 101-109.
21. Rychak JJ, Graba J, Cheung AM, et al. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 2007; 6 (5): 289-296. (Pubitemid 350013534)
22. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008; 248 (3): 936-944.
23. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246 (2): 508-518.
24. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008; 27 (6): 855-866.
25. Marshall D, Pedley RB, Boden JA, Boden R, Melton RG, Begent RH. Polyethylene glycol modifi cation of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 1996; 73 (5): 565-572. (Pubitemid 26068858)
26. Meyer DL, Schultz J, Lin Y, et al. Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci 2001; 10 (3): 491-503. (Pubitemid 32221140)
27. Gao J, Huang S, Li M, Luo R, Wang X, Takashima A. GM-CSF-surface-modifi ed B16.F10 melanoma cell vaccine. Vaccine 2006; 24 (25): 5265-5268. (Pubitemid 43818206)
28. Pillai R, Marinelli ER, Swenson RE. A flexible method for preparation of peptide homo-and heterodimers functionalized with affi nity probes, chelating ligands, and latent conjugating groups. Biopolymers 2006; 84 (6): 576-585.
29. Shrivastava A, von Wronski MA, Sato AK, et al. A distinct strategy to generate high-affi nity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 2005; 18 (9): 417-424.
30. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48 (10): 2641-2658.
31. Willmann JK, Cheng Z, Davis C, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008; 249 (1): 212-219.
32. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006; 281 (10): 6625-6631. (Pubitemid 43847597)
33. Kaufmann BA. Ultrasound molecular imaging of atherosclerosis. Cardiovasc Res 2009; 83 (4): 617-625.
34. Klibanov AL. Preparation of targeted microbubbles: ultrasound contrast agents for molecular imaging. Med Biol Eng Comput 2009; 47 (8): 875-882.
35. Klibanov AL. Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. Bioconjug Chem 2005; 16 (1): 9-17.
36. Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998; 98 (1): 1-5.
37. Alonso A, Della Martina A, Stroick M, et al. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 2007; 38 (5): 1508-1514. (Pubitemid 46684166)
38. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 1993; 90 (16): 7533-7537.
39. Millauer B, Wizigmann-Voos S, Schnürch H, et al. High affi nity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72 (6): 835-846. (Pubitemid 23110226)
40. Liang WC, Wu X, Peale FV, et al. Crosss-pecies vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281 (2): 951-961.
41. Crawford Y, Ferrara N. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Methods Enzymol 2008; 445: 125-139.
42. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor ex pression. J Nucl Med 2006; 47 (12): 2048-2056. (Pubitemid 47544993)